[Suppressibility of parathyroid function in primary hyperparathyroidism as estimated by nephrogenous cyclic AMP (author's transl)]
- PMID: 6282661
- DOI: 10.1507/endocrine1927.58.2_110
[Suppressibility of parathyroid function in primary hyperparathyroidism as estimated by nephrogenous cyclic AMP (author's transl)]
Abstract
The effects of calcium injection (3 mg/Kg/10 min) or oral calcium administration (calcium lactate 7.7 g) on plasma iPTH and Nephrogenous cyclic AMP (NcAMP) were studied in 6 normal controls and 13 patients with primary hyperparathyroidism. In the control subjects, plasma iPTH determined by a predominantly carboxyl-terminal antiserum was less than 0.3 ng/ml before and after both calcium loads, whereas 41 approximately 98% (mean 67%) of NcAMP was rapidly and uniformly suppressed to a level lower than the normal value. In 2 patients with primary hyperparathyroidism, iPTH was clearly reduced from 8.0 to 4.6 ng/ml and 1.6 to 0.96 ng/ml, respectively, by the calcium load. However, in the other 7 patients with primary hyperparathyroidism who showed only a slight elevation of iPTH: less than 0.3 approximately 0.9 ng/ml, the reductions in iPTH were not detected after the calcium load: less than 0.3 approximately 0.7 ng/ml. In contrast, 30 approximately 54% (1.02 approximately 3.85 nmol/dl GF) of NcAMP, which was greater than the diurnal variation, was suppressed after calcium injection in 5 patients with primary hyperparathyroidism (2 of 4 patients with urological, and 3 of 5 patients with chemical hyperparathyroidism). But NcAMP was not suppressed in all 4 patients with skeletal hyperparathyroidism including one with proximal renal tubular dysfunction whose basal iPTH was elevated markedly but reduced clearly by the calcium load. In general, suppression of NcAMP was followed by a decrease of phosphate excretion. On the other hand, even in a patient with primary hyperparathyroidism whose NcAMP was not suppressed at all after the calcium injection, calcium infusion (15 mg/Kg/3h) resulted in some (23%) decrease in NcAMP. Oral calcium administration resulted in responses which were almost the same as those produced by calcium injection. These results suggest that NcAMP provides a useful index in the parathyroid suppression test in patients with primary hyperparathyroidism, especially those who display a rather mild elevation of iPTH. This is not the case, however, in a few patients who show a marked elevation of iPTH and/or proximal renal tubular dysfunction.
Similar articles
-
Effects of the intravenous administration of calcium on nephrogenous cyclic AMP: use as a parathyroid suppression test.J Clin Endocrinol Metab. 1978 Mar;46(3):477-87. doi: 10.1210/jcem-46-3-477. J Clin Endocrinol Metab. 1978. PMID: 221521
-
Nephrogenous cyclic AMP as a parathyroid function test.Nephron. 1979;23(2-3):136-41. doi: 10.1159/000181623. Nephron. 1979. PMID: 220548
-
Maximal PTH secretory rate and set point for calcium in normal subjects and patients with primary hyperparathyroidism. In vivo studies.Miner Electrolyte Metab. 1988;14(4):221-8. Miner Electrolyte Metab. 1988. PMID: 2850460
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Coexisting hyperparathyroidism with thyrotoxicosis.J Endocrinol Invest. 1991 Apr;14(4):305-10. doi: 10.1007/BF03346819. J Endocrinol Invest. 1991. PMID: 1865080 Review.